The Longevity Health Company (TLHC) Ratios
The Longevity Health Company Ratios
TLHC's free cash flow for Q2 2024 was $4.36K. For the 2024 fiscal year, TLHC's free cash flow was increased by $0.00 and operating cash flow was $4.36K. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Liquidity Ratios | |||
| Current Ratio | 0.00 | 0.00 | 0.00 |
| Quick Ratio | 0.00 | 0.00 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Solvency Ratio | -0.02 | -0.02 | -0.04 |
| Operating Cash Flow Ratio | -0.00 | -0.00 | -0.00 |
| Short-Term Operating Cash Flow Coverage | -0.00 | -0.01 | -0.00 |
| Net Current Asset Value | $ -8.43M | $ -8.05M | $ -7.68M |
| Leverage Ratios | |||
| Debt-to-Assets Ratio | 327.17 | 140.88 | 145.23 |
| Debt-to-Equity Ratio | -0.36 | -0.38 | -0.40 |
| Debt-to-Capital Ratio | -0.57 | -0.62 | -0.66 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.00 | -0.00 | -0.00 |
| Debt Service Coverage Ratio | -0.01 | -0.00 | -0.00 |
| Interest Coverage Ratio | -0.07 | -0.04 | -0.01 |
| Debt to Market Cap | 0.65 | 1.62 | 0.81 |
| Interest Debt Per Share | 0.02 | 0.02 | 0.02 |
| Net Debt to EBITDA | -130.20 | -233.25 | -604.78 |
| Profitability Margins | |||
| Gross Profit Margin | 0.00% | 39.49% | 24.69% |
| EBIT Margin | 0.00% | -77.71% | -22.15% |
| EBITDA Margin | 0.00% | -77.72% | -22.13% |
| Operating Profit Margin | 0.00% | -77.72% | -22.15% |
| Pretax Profit Margin | 0.00% | -2173.17% | -2412.73% |
| Net Profit Margin | 0.00% | -2173.17% | -2412.73% |
| Continuous Operations Profit Margin | 0.00% | -2173.17% | -2412.73% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 1605.78% | 2796.01% | 10891.80% |
| Return on Assets (ROA) | -4035.01% | -1688.79% | -2613.66% |
| Return on Equity (ROE) | 4.49% | 4.57% | 7.15% |
| Return on Capital Employed (ROCE) | 0.28% | 0.16% | 0.07% |
| Return on Invested Capital (ROIC) | 0.44% | 0.26% | 0.11% |
| Return on Tangible Assets | -4035.01% | -2192.75% | -3431.55% |
| Earnings Yield | -8.01% | -19.46% | -14.52% |
| Efficiency Ratios | |||
| Receivables Turnover | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.78 | 1.08 |
| Working Capital Turnover Ratio | 0.00 | -0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -177947.22 | -98888.17 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 177947.22 | 98888.17 |
| Operating Cycle | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.00 | -0.01 | -0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | -1.35 | -0.24 |
| Free Cash Flow Yield | -0.03% | -1.21% | -0.14% |
| Valuation Ratios | |||
| Price-to-Earnings (P/E) Ratio | -12.49 | -5.14 | -6.89 |
| Price-to-Sales (P/S) Ratio | 0.00 | 111.68 | 166.17 |
| Price-to-Book (P/B) Ratio | -0.56 | -0.23 | -0.49 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3089.14 | -82.58 | -695.30 |
| Price-to-Operating Cash Flow Ratio | -3089.14 | -82.58 | -695.30 |
| Price-to-Earnings Growth (PEG) Ratio | -2.37 | 0.15 | 0.00 |
| Enterprise Value Multiple | -330.72 | -376.94 | -1355.50 |
| Enterprise Value | 7.79M | 4.95M | 6.82M |
| EV to EBITDA | -330.72 | -376.94 | -1355.50 |
| EV to Sales | 0.00 | 292.97 | 300.03 |
| EV to Free Cash Flow | -5094.92 | -216.63 | -1255.42 |
| EV to Operating Cash Flow | -5094.92 | -216.63 | -1255.42 |
| Tangible Book Value Per Share | -0.04 | -0.04 | -0.04 |
| Shareholders’ Equity Per Share | -0.04 | -0.04 | -0.04 |
| Tax and Other Ratios | |||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 |
| Interest Burden | 16.06 | 27.97 | 108.92 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.00 | 0.06 | 0.01 |
Currency in USD
